Journal article
Glucose indices, health behaviors, and incidence of diabetes in Australia: The Australian diabetes, obesity and lifestyle study
DJ Magliano, ELM Barr, PZ Zimmet, AJ Cameron, DW Dunstan, S Colagiuri, D Jolley, N Owen, P Phillips, RJ Tapp, TA Welborn, JE Shaw
Diabetes Care | Published : 2008
DOI: 10.2337/dc07-0912
Abstract
OBJECTIVE - This national, population-based study reports diabetes incidence based on oral glucose tolerance tests (OGTTs) and identifies risk factors for diabetes in Australians. RESEARCH DESIGN AND METHODS - The Australian Diabetes, Obesity and Lifestyle Study followed-up 5,842 participants over 5 years. Normal glycemia, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes were defined using World Health Organization criteria. RESULTS - Age-standardized annual incidence of diabetes for men and women was 0.8% (95% CI 0.6-0.9) and 0.7% (0.5-0.8), respectively. The annual incidence was 0.2% (0.2-0.3), 2.6% (1.8-3.4), and 3.5% (2.9-4.2) among those with normal glycemi..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by National Heart Foundation Australia
Awarded by NHMRC
Funding Acknowledgements
E.L.M.B. is supported by a National Health and Medical Research Council (NHMRC) (no. 379305)/National Heart Foundation Australia (no. PP 05M 2346) joint postgraduate scholarship. D.W.D. is supported by a Victorian Health Promotion Foundation Public Health Research Fellowship. A.J.C. is supported by a National Heart Foundation Australia Postgraduate scholarship (no. PP 04M 1794). The AusDiab study, coordinated by the International Diabetes Institute, gratefully acknowledges the generous support given by the NHMRC (grant no. 233200); the Australian Government Department of Health and Ageing; Abbott Australasia; Alphapharm; AstraZeneca; Aventis Pharma Bristol-Myers Squibb; City Health Centre, Diabetes Service, Canberra; Department of Health and Community Services, Northern Territory; Department of Health and Human services, Tasmania the Department of Health, New South Wales; the Department of Health, Western Australia; the Department of Health, South Australia; the Department of Human Services, Victoria; Diabetes Australia Diabetes Australia Northern Territory; Eli Lilly Australia; Estate of the Late Edward Wilson; GlaxoSmithKline the Jack Brockhoff Foundation; Janssen-Cilag; Kidney Health Australia; Marian & FH Flack Trust; Menzies Research Institute; Merck Sharp & Dohme; Novartis Pharmaceuticals Novo Nordisk Pharmaceuticals Pfizer; Pratt Foundation; Queensland Health Roche Diagnostics Australia Royal Prince Alfred Hospital, Sydney; and Sanofi Synthelabo.